AstraZeneca COVID-19 Antibody Could Be Solution For Vulnerable But Not Vaccine Alternative
Long-Acting Drug Filed With FDA
AZD7442 can provide antibodies in people who cannot generate their own after vaccination but could in theory also be used to protect other groups, including unvaccinated populations.
You may also be interested in...
AstraZeneca Shrugs Off COVID Antibody’s Inferiority In Therapy Setting, Sees Prevention As Main Role
AstraZeneca’s anti-SARS-CoV-2 antibody product is unlikely to rival Regeneron or Vir/GSK’s offerings in mild-to-moderate patients, where Merck’s newly-submitted oral molnupiravir will also change treatment.
Reports indicate a 13 August CDC advisory committee meeting may be used to address an amended FDA emergency use authorization to allow immunosuppressed Americans to get additional COVID-19 vaccine doses. Such a move would not run afoul of the World Health Organization’s plea for a moratorium on boosters in the general population until much of the world initially can be vaccinated.
As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.